SciELO - Scientific Electronic Library Online

vol.79 número6Inequidades en el diagnóstico de anomalías congénitas mayores en recién nacidos en Cali, ColombiaGonadotropina coriónica en flujo vaginal para el diagnóstico de rotura prematura de membranas índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Revista chilena de obstetricia y ginecología

versión On-line ISSN 0717-7526


MONTERROSA-CASTRO, Alvaro  y  PORTELA-BUELVAS, Katherin. Manejo de la atrofia vulvovaginal posmenopáusica. Rev. chil. obstet. ginecol. [online]. 2014, vol.79, n.6, pp.489-501. ISSN 0717-7526.

Objective: To identify the available therapeutic proposals for the management of the atrophic vulvovaginitis or vulvovaginal atrophy in postmenopause (VVAP) or genitourinary syndrome of menopause. Methods: Thematic review without intervention in which there was included articles whose main criterion was treatment and management of the VVAP, obtained after search in the databases: Pubmed, Science Direct, Embase, Medline and Scielo. 2119 titles were considered appropriate, 136 were adjusted to the aim and in 87 relevants information was identified. Results: Different therapeutic strategies have shown effectiveness for the treatment of the VVAP. Changes in the lifestyle, as to avoid the smoking habit, to prevent the obesity, to do exercise and to practice sexual activity, could be beneficial. The vaginal moisturizers and lubricants are the first-line therapies for the improvement of the VVAP, the first ones are administered permanently and the last ones are used during the coitus. There is controversy about the importance of the D vitamin, soya isoflavones and different herbs. The local estrogen therapy is the most effective therapeutic and it always must be preferred in severe VVAP. It could be estriol, estradiol, conjugated estrogens or estrone. The ospemifene, a selective estrogen-receptor modulator, is approved for the VVAP. The TSECs are in research, few information exists about the effectiveness of DHEA and the results with the STEAR are good. Initial studies have indicated the benefits of the fractional CO2 laser. Conclusions: Different measures are appropriate to treat the VVAP, in order that the women preserve a healthy vagina and enjoy the sexual activity.

Palabras clave : Postmenopause; atrophic vaginitis; estrogen.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons